Pharmaceutical Executive: June 2025

View the Pharmaceutical Executive June 2025 issue in an interactive format.

Not lost in the mix of June's wide-ranging coverage in Pharmaceutical Executive is an honest take on what guest thought leaders argue is “undoubtedly” the hardest job in biopharma.

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.

Dive into a sampling of data drivers—and expanded insights—poised to impact and reshape our annual leaderboard.

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Special Guest Opinion: A reimagined regulatory framework for the life sciences is not just pro-investor—it is pro-patient.

Jim Weiss, founder and chairman of Real Chemistry, and the 2025 HBA Honorable Mentor, discusses the foundation and journey behind his lifelong advocacy for mentorship—and, cliché or not, the lasting power of “you get what you give.”

Strategies and recommendations for driving value in today’s AI-enhanced prescribing environment.

Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through transparency, storytelling, and leveraging data to improve patient care.

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

For a growth mindset to truly take hold, leaders must create space for those possibilities to thrive.

Market access is about aligning internal strategies with external realities that often change without warning and at a frequency likely not experienced by other biopharma executive roles.